(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth.
Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue.
Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Eli Lilly and Novo Nordisk are among the most influential pharmaceutical companies in the rapidly expanding GLP-1 receptor agonist market, which targets diabetes and obesity. As competition intensifies and regulatory and pricing dynamics evolve, the divergence in their stock performance has become increasingly pronounced.
A wave of industry leaders—including GOOGL, LLY, JNJ, ALB, and SQM—hit fresh 52-week highs on November 19, 2025, as bullish momentum swept through tech, healthcare, retail, and commodities. Backed by earnings strength, sector tailwinds, and macroeconomic stability, the market rally highlights renewed investor appetite for growth. Tickeron’s AI robots further confirm the momentum, identifying high-probability signals across these surging names.
Verona Pharma's stock soared 122% in just three months, culminating in Merck's $10 billion acquisition. Learn how breakthrough COPD drug Ohtuvayre, stellar sales growth, and expert execution transformed this biotech into a blockbuster success.
ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…
The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.
The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.
A small-molecule drug is an organic compound characterized by a relatively low molecular weight.
The cellular sector, encompassing a group of companies including AMGN, PHI, VCEL, and QNRX, has recently experienced a significant increase in performance, with a notable 3.33% gain over the past week. However, a closer look reveals a negative outlook on this group, as supported by the Aroon Indicator and other technical analysis tools.
As we step into September 2023, investors are keenly looking for opportunities to enhance their income streams. Dividend stocks, known for their consistent payouts and potential for capital appreciation, remain a favorite among seasoned investors. Here, we'll delve into the top dividend stocks for this month, considering their past performance, dividend history, and future prospects.
Join the ranks of smart traders who have already experienced the benefits of Tickeron's robust algorithm. Don't let market uncertainty hold you back any longer – take control of your financial future with a strategy that can withstand the test of time.
Exploring the Biotech Boom - Inflammation Theme Soars +9.15% in a Week!
Discover the dynamic world of biotech and pharmaceuticals as we delve into the exciting developments within the inflammation theme. This captivating sector has seen a remarkable surge of +9.15% in just one week, leaving investors buzzing with anticipation. With key players like Coherus BioSciences, Pfizer, Johnson & Johnson, and more driving the theme's momentum, the potential for groundbreaking treatments and life-changing solutions is evident. Join us as we explore the fascinating market movements and sectoral shifts shaping the future of healthcare and revolutionizing the way we combat diseases related to cell proliferation. Don't miss out on this captivating journey into the world of medical innovation and investment opportunities!
Explore the potential of Therapy theme stocks showing a stellar 1-week gain of 10.96%. Understand our Long-Short Equity Strategy delivering a 64% annualized return, and High Capitalization Swing trading with a 7% annual return. Discover key insights on $ACRS, $ALLO, $ALNY, and others.
Last week witnessed a strong performance from biotech firm Amgen (AMGN), with an artificial intelligence (AI)-based trading robot facilitating a 4.47% gain. This feat underlines the growing potential of AI in stock market trading. Specifically, the AI trading robot was able to leverage technical analysis, using the Moving Average Convergence Divergence (MACD) indicator, to exploit the inherent market opportunities.
The dynamics in our robots remain impressive, and we comfortably outperform all indices. Today, I would like to highlight one of our robots, Swing-Trader-Popular-Stocks-TA-FA, which specializes in trading stocks with high volatility, particularly like ABBVIE INC. "ABBV."
One such innovation is the emergence of AI trading robots that promise to navigate the complexities of the stock market and deliver substantial returns. In this article, we analyze the recent performance of an AI trading robot accessible at "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" and explore how it generated an impressive +3.98% gain while trading ABBV during the previous week. Additionally, we examine the company's momentum indicator and its implications for potential traders.
Explore the successful swing trade approach for PFE, generating a 5.49% yield through in-depth Trend Analysis (TA). Witness the power of predictive RSI indicators as PFE ascends from the oversold realm. Learn how precision TA aids effective swing trading and boosts returns. Join us to enhance your trading skills and profits.